On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency ...

Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. | Nephron ...